ANTICIPATE Study Update

The last subject was included in the ANTICIPATE study in October 2017 and the last study visit took place in January 2018. Database lock took place in March 2018.

Currently the ANTICIPATE team is finalizing data analysis and manuscript writing, and have started discussions about the implications of the study findings for the Phase III trial (WP7B) with DAV132.

Preliminary results were presented with a poster at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in 2018. Data were also presented during the COMBACTE networking event which took place during ECCMID, and at the national congress of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), the Spanish society of infectious diseases and clinical microbiology.

This observational study was conducted with 1,007 patients aged over 50 receiving broad-spectrum antibiotics in the hospital. They were recruited in 34 European clinical centers in the Netherlands, Germany, Greece, Spain, Romania and France. Recruited patients were followed over a three-month period to detect any occurrence of Clostridium difficile infections following antibiotic treatment. The aim is to identify the risk factors for these infections, establishing for whom the prevention of this pathology will prove the most beneficial.

The ANTICIPATE study started in 2016, with the French biotechnology company Da Volterra as EFPIA partner. ANTICIPATE also aims to support the development of DAV132, Da Volterra’s promising new therapeutic agent for the prevention of Clostridium difficile infections in high-risk patients. The product, DAV132, given with antibiotic treatment, decreases the residues of antibiotics in colon, and protects the intestinal microbiota from antibiotics-induced alterations. In patients, DAV132 is expected to prevent CDI and the occurrence of resistant pathogens.

COMBACTE’s collaboration with Da Volterra is also highlighted in the 2^ndedition of the COMBACTE magazine, in an interview with Marie-Noëlle Bouverne, Da Volterra’s Director of Clinical Operations. Read her interview on page 50.